Objectives: The presentation will focus on advancements in chemical peels tailored for body treatments, with a specific focus on their application and efficacy in skin of colour. We will explore the latest indications and innovative approaches in using chemical peels to address various skin concerns beyond facial treatments. The discussion will highlight evidence-based practices and recent research, aiming to provide a comprehensive update on the expanded use of advanced chemical peels in diverse skin types and avoidance of complications in darker skins .

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: Here, a novel serum containing 2-MNG, an ingredient that quenches melanin precursors (Routine A) has been compared to a tyrosinase inhibitor containing dermocosmetic serum (Routine B).

Introduction: Acne-induced post inflammatory hyper pigmentation (PIH) is a frequent, difficult to treat, condition. Topical treatments used to reverse the condition are most often based on tyrosinase inhibition with either drugs or dermocosmetics. Here, a novel serum containing 2-MNG, an ingredient that quenches melanin precursors (Routine A) has been compared to a tyrosinase inhibitor containing dermocosmetic serum (Routine B). Both serums were used in conjunction with a broad spectrum SPF50+/UVA sunscreen.

Materials / method: A single center randomized, double blind, parallel group, 12 weeks study has been conducted in one center in Mauritius from February to October 2023. Subjects had mild acne on the face (GEA =2 and <9 inflammatory lesions) and moderate to severe PIH with a PAPHI score >10. Patients had to apply both serums at home on the face twice a day in the morning and in the evening. The sunscreen had to be applied in the morning and at the beginning of the afternoon. Evaluations conducted at D0, D28, D56, D84 included PAHPI score, mean darkness of PIHP lesions (from 0 to 8) ), local and global tol

Results: The study involved 77 subjects including 92% females with diverse phototypes. Both routines showed a significant decrease of PIHP severity at D84 according to the PAHPI score. This decrease was significant since D28. The % of improved subjects rated by investigators at D84 was higher with routine A. Routine A showed a faster and significantly greater decrease in the PAHPI number of PIHP lesions sub-score. The two routines displayed a significant and similar improvement on mean darkness. 60% and 57% of subjects respectively in group A and B perceived that their PIHP were improved.

Conclusion: This study shows that both routines comprising innovative depigmenting serum and a broad spectrum SPF50+/UVA sunscreen are effective on PIHP with a twice daily application over 3 months. The patients’ self-perceived level of improvement suggests a clinically relevant effect from both routines. Routine A, containing the new melanin quencher, showed better efficacy on several secondary criteria related to PIHP and cosmetic outcomes.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: La Roche-Posay Laboratoire Dermatologique

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: La Roche-Posay Laboratoire Dermatologique

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： La Roche-Posay Laboratoire Dermatologique

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: Nevus of Ota (Oculodermal melanocytosis) is a dermal melanocytic hamartoma that presents in childhood or at adolescence as bluish/slate gray hyperpigmentation along the first or second branch of trigeminal nerve.
The pigmentation progressively increases in size and color till puberty.

To understand the presentation, prognosis and treatment of Nevus of Ota. Also how to deal with some difficult situations in this condition. Will be introducing some additional maneuvers to hasten the clearance of pigment in nevus of ota patients.

Introduction: Laser technology – Wonder of present-day therapeutics.
Tremendous advances have happened since Ruby Laser was used for the first time.
Goldman in 1960s used a Q-switched ruby laser (50-microsecond pulse duration) and found that the damage threshold of pigmented lesions was independent of skin color.
Q-switched Nd:YAG laser (QSNYL) has been used successfully to treat nevus of Ota lesions.
Most of the patients do well
However, there are some cases that pose challenges

Materials / method: We did a study to assess the efficacy and safety of Q Switched Nd:YAG Laser (QSNYL) in an open labeled prospective study involving 44 Indian patients with nevus of Ota.
In 10 years >100 patients taken up for treatment of various pigmented lesions.
Most of the patients have completed treatment while some are still on it.
Total Patients - 105
Nevus of Ota - 44
PEN - 46
Freckles /Lentigenes - 11
Becker Nevus - 04
We used different maneuvers like an additional pass of fractional CO2 and different spot sizes for the QSL.

Results: Total patients - 44
50 to 75 % clearance - 31
25 to 50 % clearance - 10
< 25 % clearance - 03

Nevus of Ota
Total patients - 44
50 to 75 % clearance - 31
25 to 50 % clearance - 10
< 25 % clearance - 03

Conclusion: Several pigment-specific lasers can effectively treat epidermal and dermal pigmented lesions.
Lasers are most effective in treating epidermal pigmented lesions (eg, lentigines, ephelides).
Nevus of Ota is unique amongst the pigmented dermal lesions in that near-total clearance is often seen after laser treatment.
QS Lasers are the treatment of choice for the treatment of NOO
These lasers have revolutionised the prognosis of this otherwise difficult to treat condition
The addition of CO2 fractional laser pass and mutiple spot sizes of QSL helps clear the pigment faster and more effectively

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: Solta

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。